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Abstract (Word Count: 225)   
Aims: To explore possible associations that may explain the greater benefit from Cardiac Resynchronization 
Therapy (CRT) reported amongst women. 
Methods and Results: In an individual patient data (IPD) meta-analysis of five randomized controlled trials, 
all-cause mortality and the composite of all-cause mortality or first hospitalisation for heart failure (HF) were 
compared among 794 women and 2702 men assigned to CRT or a control group. Multivariable analyses 
were performed to assess the impact of sex, QRS duration, HF aetiology, left ventricular end-diastolic 
diameter  (LVEDD), and height on outcome. Women were shorter, had smaller LVEDD, more often left 
bundle branch block (LBBB), and less often ischaemic heart disease (IHD), but QRS duration was similar 
between sexes. Women tended to obtain greater benefit from CRT but sex was not an independent predictor 
of either outcome. For all-cause mortality, QRS duration was the only independent predictor of CRT benefit. 
For the composite outcome, height and QRS duration, but not sex, were independent predictors of CRT 
benefit. Further analysis suggested increasing benefit with increasing QRS duration amongst shorter patients, 
of whom a great proportion were women.   
Conclusions: In this IPD meta-analysis CRT benefit was greater in shorter patients, which may explain 
reports of enhanced CRT benefit among women. Further analyses are required to determine whether 
recommendations on the QRS threshold for CRT should be adjusted for height.     
(ClinicalTrials.gov numbers, NCT00170300, NCT00271154, NCT00251251). 
Key Words: Cardiac resynchronization therapy, heart failure, gender, height 
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INTRODUCTION 
Cardiac resynchronization therapy (CRT) is an established therapy for symptomatic patients with 
heart failure (HF), a reduced left ventricular (LV) ejection fraction (EF), and electrical dyssynchrony.1-8 
Previous reports have shown that women may obtain greater benefit than men from CRT but the reason for 
this has not been fully clarified. Healthy women have smaller hearts9 and a slightly shorter QRS duration10, 11 
than men and have been reported to benefit from CRT at a shorter QRS duration.12, 13 In trials of CRT, 
women are also more likely to have non-ischemic cardiomyopathy and left bundle branch block ( LBBB),14 
two characteristics that are associated with greater reverse LV remodeling with CRT15 and hence potentially, 
with greater clinical benefit.  
Individual patient-data (IPD) meta-analysis allows investigation of the interaction amongst variables 
which conventional meta-analysis of aggregate data does not. In a previous IPD meta-analysis, we identified 
QRS duration as the only independent predictor of morbidity and mortality benefit after adjusting for other 
variables.16 In this IPD meta-analysis, we explored differences in the benefits of CRT for men and women 
and whether these appeared directly related to sex or whether sex acted as a surrogate for other features that 
might provide plausible alternative explanations. 
 
Methods  
Individual patient data from five substantial randomized controlled trials comparing CRT to no CRT with at 
least six months follow-up sponsored by Medtronic were used in this analysis. Data were pooled on 4,317 
patients comparing either CRT with no active control (no device or back-up pacing); CARE-HF,3 
MIRACLE,1 REVERSE4, 5 or CRT-D with ICD (REVERSE,4, 5 MIRACLE-ICD,6 RAFT.7 In the control arm 
back-up right ventricular pacing (VVI) was programmed to allow for intrinsic rhythm as much as possible 
and was VVI-30 in MIRACLE1 and VVI-35 in MIRACLE- ICD6 and REVERSE.4, 5  
In order to create a more homogeneous population, patients in New York Heart Association (NYHA) 
class I (107 patients from REVERSE) and those in atrial fibrillation or with a pre-existing pacemaker (338 
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patients from RAFT) were excluded. The remaining patients were in sinus rhythm with NYHA III/IV 
(CARE HF, MIRACLE, MIRACLE ICD) or NYHA II (MIRACLE ICD, REVERSE) and on guideline-
recommended HF therapy before being randomized.  
The two outcomes of interest specified for this analysis were all-cause mortality and the composite 
of first hospitalisation for HF (HFH) or all-cause mortality. Hospitalisations were adjudicated by committees 
blinded to treatment allocation in each study.  
Our previous univariate analyses16 have demonstrated that the baseline variables: age, sex, NYHA 
class, ischaemic aetiology, QRS duration, LVEF, beta blocker use, and systolic blood pressure predicted 
clinical outcomes. Thus, these variables, considered the core covariates, were included in all models. Prior 
analyses also showed QRS duration to have a linear interaction with the effect of CRT for mortality, and a 
non-linear interaction for the composite of mortality or first HF hospitalisation.16  
Core-laboratory values were used for electrocardiographic measurements in all studies and for 
echocardiographic assessment of LVEF in all studies except RAFT. Body mass index (BMI) was calculated 
as (weight (kg)/[height (m)]2). Lean body mass (LBM) was calculated using the formula of LBM = 
0.29569×Weight (kg) + 41.813×Height (m) – 43.2933 for women, and LBM = 0.3281×Weight (kg) + 
33.929×Height (m) – 29.5336 for men.17 
 
Statistics 
Analyses were conducted according to the intention-to-treat principle meaning that they included those 
patients who failed to receive their treatment assignment.16 Continuously distributed data are shown as both 
mean and standard deviation and median, inter-quartile (IQR) and full range (FR). Categorical data are 
shown as percentages. Because data were pooled from multiple studies which may be heterogeneous for one 
or more unaccounted factors affecting outcomes, shared frailty models including the core covariates were 
used for both endpoints for each gender subgroup, with random effects for each study following a gamma 
distribution. Consistent with the findings of prior analyses, for mortality/first HF hospitalisation, a model 
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with both a linear and nonlinear interaction term between QRS duration and CRT response was fit, while for 
mortality alone only a linear interaction term was fit. Quantitative variables (age, LVEF, QRS duration, 
systolic blood pressure) were treated as continuous variables in the models. QRS duration was centered by 
subtracting 120 ms for each QRS duration.2  Patients in NYHA class III were enrolled in all but one study5 
and served as the default for calculating hazard rate. To assess variability of the results, 95% bootstrap 
confidence intervals were determined for each set of hazard ratios.   
 To study sex, we first tested CRT response over the range of QRS durations separately for men and 
women. Next, we established significant differences in baseline characteristics between men and women 
regarding HF aetiology, QRS morphology, left ventricular end-diastolic diameter (LVEDD), and 
anthropometric data such as height, BMI, and LBM. T-tests were used to compare continuous measures, 
while chi-square tests were used to test ordinal and qualitative characteristics. Based on differences observed 
between men and women, men were partitioned into terciles by height, and frailty models including the core 
covariates (excluding sex) were fit for comparison with women. Patients were also partitioned by sex and 
aetiology, and event rates per 100 patient years were calculated for each subgroup. 
To investigate the relationship between height and the effect of CRT further, frailty models were fit 
for both mortality and mortality/HF hospitalisation with the core covariate main effects (excluding sex), 
main effects for CRT, normalized QRS duration and height, and the interaction effects for CRT with 
normalized QRS duration and normalized height. For each interaction term, the model tested a linear 
interaction effect for each interaction term, and a non-linear interaction effect incorporating a third-order P-
spline with 4 degrees of freedom, which allows for fitting complicated curvilinear patterns. The latter 
interaction term was tested to determine if the hazard ratio for CRT changes over different heights and 
different QRS duration subgroups in a nonlinear manner. The predicted values from each model were used to 
determine and plot the estimated hazard ratio of CRT for QRS duration and height as continuous measures. 
A similar model was fit with LBM substituted for height.   
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A sub-analysis was performed on the patients who also had LVEDD available, to assess whether the 
effect of height was a surrogate for left ventricular size. The analysis added a main effect for LVEDD and an 
interaction effect for LVEDD with CRT to the overall model assessing height. A sub-analysis was also done 
involving the subset of patients in whom left ventricular end-systolic volume (LVESV) was available. 
 
RESULTS 
Following exclusion of patients for missing LVEF, QRS width, or systolic blood pressure, a total of 3,776 
(97.5% of available randomized patients) were included in some or all of the analyses (Figure 1). 
Measurements of height were missing in a further 280 patients. In an additional 1,023 patients, mainly from 
RAFT, LVEDD was not reported (Figure 1). The median (IQR) follow-up was 23.5 (6.2 – 38.3) months.  
 
Patient characteristics  
The median (IQR) age of patients was 66 (58-72) years and 794 (22.7%) were women (Table 1). Women 
were less likely to have IHD. QRS duration was 160 (146-176) ms and was similar in women and men, but 
women were more likely to have LBBB and less likely to have right bundle branch block (RBBB). Women 
were shorter by an average of almost 14 cm, lighter by an average of 13 kg, had similar BMI as men, but 
lower LBM. Women had a smaller LVEDD (p<0.0001) and LVESV (p<0.0001) but similar LVEF compared 
to men. Medication was similar between the sexes except that women were more likely to be prescribed 
digoxin. With regard to height (Table 2) 886 (32.7%) men were in tercile 1: median height of 167.6 (range 
165.1-169.9) cm, 935 (34.6%) were in tercile 2: median height of 175.0 (range 173.0-176.8) cm, and 881 
(32.6%) in tercile 3: median height of 182.9 (range 180.1 – 185.4) cm. QRS duration and prevalence of 
LBBB was similar across terciles.  The height of women ranged between 120.9-185.9 cm. Due to the smaller 
sample size, for the purpose of the event rate analysis women heights were therefore divided in two 
categories based on a median of 160 cm.  
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CRT effect by sex in relation to QRS duration  
Sex did not predict the response to CRT after accounting for other covariates. An interaction between CRT 
and QRS duration was observed for each sex. For the composite outcome, a non-linear interaction was 
observed for men (p=0.034) and for women (p=0.049). For mortality alone, a linear interaction was observed 
for men (p=0.0059) and, with less certainty, for women (p=0.065). For both endpoints trends toward greater 
benefit amongst women were observed over the QRS duration range 130-170 ms (Figure 2A/B).  
 
CRT effect by aetiology and sex  
QRS duration was smaller among patients with IHD in both men and women. For patients with IHD, more 
women (81.5%) than men (71.2%) had LBBB. Overall patients with IHD had higher event rates regardless 
of sex or whether they were assigned to CRT (Table 3). The benefits of CRT on outcomes were similar for 
women and men with IHD, whereas for patients without IHD the observed benefit of CRT was greater 
among women.   
 
CRT effect by height and sex in relation to QRS duration 
The distribution of the lowest tercile of height amongst men [168 cm (165-170)] overlapped that for women 
[160 cm (156-166)], with approximately 94% of women having a height within the range of the lowest 
tercile of men. For the composite outcome, there was a linear interaction between QRS duration and the 
effect of CRT for each tercile of height for men (Figure 3A). The estimated effect of CRT on the composite 
outcome was greatest in the shortest tercile of men for whom benefit appeared to persist even when QRS 
duration was <130ms. Similar results were noted for all-cause mortality (Figure 3B). The estimated effect of 
CRT on morbidity and mortality for the shortest tercile of men was similar to that observed for women and 
greater than in the two taller terciles of men. Bisecting women by height showed similar estimated hazard 
ratios across height among women (Table 4). In the patients assigned to the control group the event rates 
were higher in shorter patients (lowest tercile of men and lower half of women by height range).  
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Main modelling results for outcomes and interaction with effect of CRT 
Interaction between height and CRT, accounting for other covariates, was further assessed by ignoring sex 
and treating height as a continuous variable. Models adjusting for previously determined significant 
covariate main effects, as well as interaction between QRS duration and CRT, showed a linear interaction 
between height and CRT (p=0.013) for mortality/HF hospitalisation (Table 5), but not for mortality alone. 
Plotting the estimated hazard ratio for both height and QRS showed that the effect of CRT on the composite 
outcome was most pronounced amongst shorter patients with QRS between 160 and 190 ms (Figure 4A and 
B). As can be seen in Figure 4B, the greater the QRS duration and the shorter the height, the lower the 
estimated hazard ratio for CRT benefit. This contour plot suggests that for  patients with a QRS duration of 
at least 150 ms, taller patients may still benefit from CRT as the estimated hazard ratio for patients with QRS 
= 150 ms does not reach 1.0 until height is approximately 195 cm. For some patients with a QRS of 120-149, 
height may mitigate the potential benefit of CRT with regard to mortality/first HF hospitalization, as for 
example the estimated CRT hazard ratio for patients with QRS = 135 is less than 1 if height is less than 
approximately 172 cm, and the estimated CRT hazard ratio for patients with QRS = 120 is less than 1 if 
height is less than approximately 160 cm.  
When an interaction term for sex and CRT was added to the composite outcome model, the 
height/CRT interaction term was no longer significant, suggesting confounding between the effect of sex and 
height. The model for the composite outcome was repeated substituting LBM for height, but neither the main 
effect for LBM (p=0.61) nor the interaction with CRT, both linear (0.089) and non-linear (p=0.28), were 
statistically significant.  
Measurements of both height and LVEDD were available for 2,473 patients. Women had smaller left 
ventricular dimensions than men, but LVEDD varied little across terciles of height for men (Table 2). 
LVEDD corrected for height was similar in women and men in the shortest two terciles of height, but was 
smaller in the tallest men. When the model for the composite outcome was expanded to include a main effect 
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for LVEDD and an interaction effect for LVEDD with CRT, the interaction between height and CRT 
remained significant. Although the main effect for LVEDD was also significant, the interaction between 
LVEDD and CRT was not (Supplementary Table 1). This suggests that height may not simply be a surrogate 
for LV size.   
Finally, to assess the potential confounding effect of LVESV, a model for the composite outcome 
was fit with interaction effects for CRT with QRS duration, and CRT with LVESV, along with main effects 
for age, NYHA, baseline beta blocker usage, aetiology, LVEF, QRS duration, LVESV, and systolic blood 
pressure. While the interaction effect for QRS duration remained significant, neither the main effect for 
LVESV (p=0.32) nor the interaction between LVESV with CRT (p=0.85) was significant. Consequently, 
further analyses including both LVESV and height were not explored. 
 
DISCUSSION 
In this individual patient data meta-analysis, height and QRS duration but not sex independently predicted 
the ability of CRT to reduce the composite endpoint of heart failure hospitalisation and mortality. Patients of 
shorter stature more consistently gained benefits from CRT across the range of QRS duration 160-190 ms. 
CRT also appeared to provide a greater reduction in mortality amongst shorter patients, although only QRS 
duration was an independent predictor of benefit. Men in the shortest tercile appeared to have a prognostic 
benefit from CRT even when QRS duration was <130 ms. Differences in height appeared to account for why 
CRT conferred greater benefit for women than for men. Sex may thus act as a surrogate for height and 
possibly for other factors, such as QRS morphology, aetiology of ventricular dysfunction, or LV dimensions, 
that all may influence the response to CRT. It is unknown, however, whether the possible confounding 
results in sex were masking the effects of these factors or vice versa, as the modeling could not effectively 
assess the possible influence of sex when adjusting for height. Men significantly more often had IHD than 
women, with higher observed rates across all terciles, making it less likely that our results across terciles of 
men were explained by difference in presence of IHD. Our results suggest that although QRS duration is the 
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key selection criterion for CRT, stature might also be taken into account in patient selection for CRT when 
QRS duration lies in the range of 130-160 ms.  
Historically, in clinical trials of CRT, only 20% of patients enrolled were women, making it difficult 
in individual studies to interpret possible differences between the sexes in their response to CRT. 
Conventional meta-analysis of aggregate data increases the power to detect the effect of an intervention in 
subgroups but unlike IPD does not permit investigation of the interaction between sex and other variables. 
Our prior IPD meta-analysis showed that sex was not an independent predictor of the effect of CRT on 
morbidity or mortality after adjusting for other variables; only QRS duration predicted benefit.16 In this 
analysis, we show that this relationship between QRS duration and the benefit of CRT exists for both men 
and women. 
Retrospective analyses of the MADIT-CRT trial of HF patients in NYHA I-II and not included in 
this analysis, suggested that LBBB, a subgroup that was not pre-specified, was associated with greater 
benefit from CRT,13 which has had a major impact on CRT guidelines.2,8 LBBB is more prevalent amongst 
women, which might explain differences in the effect of CRT between the sexes.11-13 Others have suggested 
that amongst patients with LBBB, women benefit from CRT-D at shorter QRS durations than men.18 
However, in an analysis of MADIT-CRT confined to patients with LBBB, the effect of CRT-D on both 
morbidity and mortality was greater amongst women,19 suggesting that female sex contributed to CRT 
benefit. Accordingly, differences in the prevalence of LBBB does not appear to be key to the greater benefit 
of CRT amongst women. Analyses of trials of CRT other than MADIT-CRT have generally not supported a 
greater benefit of CRT amongst patients with LBBB.20 In an IPD meta-analysis larger than the present one 
and comprising all of the main trials of CRT, including from three different manufacturers and across a range 
of NYHA classes, older age, QRS duration >150 ms, and female sex were associated with a greater 
prognostic benefit from CRT; LBBB was not an independent predictor of benefit although the authors 
retained it in their prognostic model.21 However, QRS duration was not analyzed as a continuous variable, 
which weakens its contribution in prediction models. In the current IPD meta-analysis, where QRS duration 
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was used as a continuous variable, LBBB was more common amongst women but it was not an independent 
predictor of response after accounting for QRS duration.  
In CRT trials, women are also less likely to have IHD as the cause of LV dysfunction.14 Patients with 
IHD in CRT trials are less likely to have LBBB and have shorter QRS durations, smaller LV volumes, and 
less pronounced reverse LV remodeling after CRT,15 all of which might be expected to lead to a worse 
response to CRT. In our analysis, although patients with IHD had a worse outcome than those with dilated 
cardiomyopathy, they obtained similar relative and therefore somewhat greater absolute benefit from CRT 
regardless of sex.16 This suggests that mechanisms other than reverse remodeling account for some of the 
therapeutic benefits of CRT16, 19, 22 and that IHD should not be used as a selection criterion.   
In a previous single center study of 212 patients with dilated cardiomyopathy and LBBB, LV reverse 
remodeling with CRT was greater in women than in men and occurred at smaller QRS duration.12 This effect 
was not explained by differences in body surface area but by adjustment for LV mass and end-diastolic 
volume.23 In our analysis, median LVEDD was smaller amongst women compared to men regardless of 
tercile in height. On average, healthy women have smaller hearts than men24 but this difference is largely 
accounted for by differences in height.25 Shorter patients will have relatively more LV dilatation for a given 
LV dimension than a tall person. In our analysis, after correction for height, women and men in the shorter 
two terciles had similar LVEDD, but men in the tallest tercile had relatively less LV dilatation. The greater 
benefit of CRT in women and shorter men might be because of greater LV dilatation relative to their pre-
morbid state. However, we did not find that LVEDD predicted benefit from CRT, whether or not height was 
included in the model.  
Shorter patients may be at higher risk for cardiovascular events. In population studies, shorter 
patients are at higher risk of coronary artery disease and stroke26 and greater risk of new onset HF.27 In our 
analysis, women and men had similar BMI but, as expected,28 LBM was lower in women as a percentage of 
body weight. Higher BMI is associated with a lower mortality for patients with heart failure,25, 29 but BMI 
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does not distinguish between fat and lean body mass. Individuals with similar BMI may have very different 
body compositions.  
An important limitation of this analysis was the restriction to those studies in which we had access to 
IPD. One distinction is that the mean age in this IPD is lower than the mean age of the overall broad 
HFpopulation and in HF surveys. Therefore, care should be taken in interpreting post-hoc analyses of 
subgroup data and in extrapolating data gathered from patients selected for a clinical trial to the wider patient 
population that might be considered for CRT. Therefore, and despite stemming from an individual patient 
data meta-analysis, our study results do not allow firm conclusions, but remain hypothesis generating.  Our 
analysis included a large number of patients with heterogeneity in symptom severity and intervention (ICD 
vs. CRT) but found that no measured patient characteristic other than QRS duration and height influenced 
the clinical benefit of CRT. Choice of baseline covariates to evaluate was predetermined by constituent trials 
and predefined for this analysis. No minimum sample size was required for subgroups. Finally, many 
patients had missing data on ventricular dimensions and volumes which will have weakened the power to 
show interactions for these variables. Race was not taken into consideration in this analysis but most patients 
were of Caucasian origin. Whether race influences the relationship between QRS duration and the effect of 
CRT is unknown but amongst healthy individuals, Africans and Asians of both sexes have a shorter QRS 
duration than Caucasians.10, 30 
In conclusion, QRS duration is the strongest predictor of the likelihood that CRT will reduce 
morbidity and mortality for patients with symptomatic heart failure, a reduced LVEF and in sinus rhythm, 
but patients who are shorter in height may also be more likely to benefit. Differences in height might account 
for the observation that women tend to benefit more from CRT than men. Whether height-corrected QRS 
duration should be used to select patients for CRT deserves further exploration.   
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LEGENDS 
Figure 1:  CONSORT flow diagram showing reasons for excluding patients from analysis. 
 
Figure 2: Estimated hazard ratios (Y-axis) and 95% confidence intervals (dotted lines) for the effects of 
CRT versus control for men (black lines) and women (red lines). Panel 2A shows the relationship between 
the effect of CRT on mortality or first HF hospitalisation and QRS. Panel 2B shows the corresponding 
relationship for mortality. The intersection of the 95% confidence interval and the line indicating a hazard 
ratio of 1.0 (no effect) indicates the QRS duration above which there is a high certainty of response. 
 
Figure 3: Estimated hazard ratios (Y-axis) for the effects of CRT versus control with QRS, for mortality or 
first HF hospitalisation (Panel 3A) and mortality alone (Panel 3B) on men partitioned by height (upper 
tercile, middle tercile, lower tercile) and women (red lines).  
 
Figure 4: Estimated hazard ratios (Z-axis) for the effects of CRT versus control on mortality/first HF 
hospitalization with QRS plotted on the X-axis and Height in cm plotted on the Y-axis. Hazard ratio 1 
marked with line. (Panel 4A) and a Contour Plot for CRT Hazard Ratio of Mortality/First HF 
Hospitalization by QRS and Height (Panel 4B).  The contours reflect the CRT hazard ratio for different 
combinations of QRS duration and height generated from Figure 4 a. This “overhead view” was created to 
facilitate the ranges of height (Y-axis) and QRS duration (X-axis) for different CRT hazard ratios.  Lighter 
blue colour corresponds to greater CRT benefit (i.e. lower hazard ratio).  
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Table 1.  Patient Characteristics  
 Women (N=794) Men (N=2702) Statistical Difference 
Men vs Women 
(N=3496) 
Study    
   MIRACLE 154 (19.4%) 325 (12.0%) P < 0.0001 
   MIRACLE ICD 103 (13.0%) 446 (16.5%)  
   CARE-HF 190 (23.9%) 526 (19.5%)  
   REVERSE 112 (14.1%) 390 (14.4%)  
   RAFT 235 (29.6%) 1015 (37.6%)  
Age    
   Mean ± STD 64.3 ± 10.8 64.9 ± 10.2 0.5 ± 10.3 
   Median (IQR) 65.9 (57.6 – 72.5) 66.0 (58.0 – 72.4) P = 0.2161 
   Range 23.0 – 89.0 20.4 – 93.8  
QRS Duration (ms)    
   Mean ± STD 161.8 ± 20.4 160.7 ± 23.3 -1.1 ± 22.6 
   Median (IQR) 160 (150 – 175) 160 (143 – 177) P = 0.1854 
   Range 94 – 263 80 – 250   
Height (cm)    
   Mean ± STD 161 ± 8 174.6 ± 7.7 13.9 ± 7.7 
   Median (IQR) 160 (156 – 166) 175.0 (169.9 – 180.1) P < 0.0001 
   Range 121 – 186 132.1 – 200.7  
Weight (kg)*    
   Mean ± STD 71.9 ± 17.0 85.1 ± 17.4 13.2 ± 17.3  
   Median (IQR) 69.0 (60 – 81.2) 82.8 (73.0 – 94.8) P < 0.0001 
   Range 37.2 – 142.7 31.3 – 188.2  
    
BMI    
   Mean ± STD 27.8 ± 6.5 27.9 ± 5.3 0.1 ± 5.6 
   Median (IQR) 26.6 (23.4 – 31.3) 27.3 (24.4 – 30.7) P = 0.8282 
   Range 14.2 – 64.3 11.4 – 70.6  
Lean Body Mass (kg)    
   Mean ± STD 45.2 ± 6.6 57.6 ± 7.2 12.4 ± 7.0 
   Median (IQR) 44.8 (40.5 – 49.1) 57.0 (52.8 – 61.8) P < 0.0001 
   Range 26.5 – 69.5 35.9 – 94.3  
Ischaemic aetiology 277 (34.9%) 1719 (63.6%) P < 0.0001 
Hypertension** 363 (45.9%) 1210 (44.9%) P = 0.6275 
NYHA    
   Class II 315 (39.7%) 1410 (52.2%) P < 0.0001 
   Class III 433 (54.5%) 1210 (44.8%)  
   Class IV 46 (5.8%) 82 (3.0%)  
Baseline MLwHF    
   Mean ± STD 48.0 ± 24.0 41.4 ± 23.4 -6.6 ± 23.6 
   Median (IQR) 48 (28 – 67) 40 (22 – 59) P < 0.0001 
   Range 0 – 105  0 – 105   
LBBB*** 704 (89.0%) 2034 (75.7%) P < 0.0001 
RBBB*** 29 (3.7%) 282 (10.5%) P < 0.0001 
LVEF (%)    
   Mean ± STD 24.4 ± 6.2 24.1 ± 6.3 -0.4 ± 6.3 
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   Median (IQR) 24.2 (20.0 – 28.3) 24.2 (20.0 – 28.0) P = 0.1554 
   Range 8.0 – 53.4 6.0 – 51.6  
LVEDD****    
   Mean ± STD 6.6 ± 0.9 7.0 ± 0.9 0.4 ± 0.9 
   Median (IQR) 6.5 (6.0 – 7.2) 7.0 (6.3 – 7.5) P < 0.0001 
   Range 4.1 – 9.6 3.9 – 12.0  
LVESV*****    
   Mean ± STD 198.3 ± 85.4 241.7 ± 98.6 43.3 ± 95.4 
   Median (IQR) 180.8 (137.9 – 241.1) 223.9 (174.8 – 288.4) P < 0.0001 
   Range 47.6 – 555.7 65.7 - 862  
Baseline Medications    
   Beta Blocker 617 (77.7%) 2112 (78.2%) P = 0.7846 
   ACE/ARB****** 755 (95.3%) 2567 (95.2%) P = 0.8954 
   Digoxin****** 372 (47.0%) 1159 (43.0%) P = 0.0472 
   Diuretics****** 713 (90.0%) 2358 (87.5%) P = 0.0507 
   Spironolactone******* 355 (47.0%) 1099 (43.7%) P = 0.1099 
*57 Subjects with missing data  
**11 Subjects with missing data  
***17 Subjects with missing data  
****1023 subjects with missing data  
*****1417 Subjects with missing data  
******8 Subjects with missing data  
*******223 Subjects with missing data 
ACE=angiotensin converting enzyme inhibitor, AII= angiotensin II receptor inhibitor, BMI= body mass 
index, IQR= interquartile range, LVEF= left ventricular ejection fraction, LBBB= left bundle branch block, 
LVEDD= left ventricular end-diastolic diameter, LVESV= left ventricular end-systolic volume, MLwHF= 
Minnesota Living with Heart Failure Questionnaire, NYHA New York Heart Association class, RBBB= 
right bundle branch block, STD= standard deviation 
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Table 2: Patient Characteristics by Height Tercile for Men 
 Women (N=794) Men (Tercile 1) 
(N=886) 
Men (Tercile 2) 
(N=935) 
Men (Tercile 3) 
(N=881) 
Study     
   MIRACLE 154 (19.4%) 92 (10.4%) 110 (11.8%) 123 (14.0%) 
   MIRACLE ICD 103 (13.0%) 95 (10.7%) 158 (16.9%) 193 (21.9%) 
   CARE-HF 190 (23.9%) 221 (24.9%) 170 (18.2%) 135 (15.3%) 
   REVERSE 112 (14.1%) 101 (11.4%) 138 (14.8%) 151 (17.1%) 
   RAFT 235 (29.6%) 377 (42.6%) 359 (38.4%) 279 (31.7%) 
Age     
   Mean ± STD 64.3 ± 10.8 66.3 ± 9.6 64.7 ± 10.5 63.6 ± 10.3 
   Median (IQR) 65.9 (57.6 – 72.5) 67.7 (59.6 – 73.3) 65.7 (57.7 – 72.8) 64.6 (57.1 – 71.1) 
   Range 23.0 – 89.0 32.6 – 87.5 20.4 – 87.8 25.5 – 93.8 
QRS Duration (ms)     
   Mean ± STD 161.8 ± 20.4 160.5 ± 22.8 159.6 ± 23.1 162.1 ± 23.8 
   Median (IQR) 160 (150 – 175) 160 (144 – 176) 160.0 (140.0 – 175.0) 160 (144 – 180) 
   Range 94 – 263 93 - 228 80 - 240 96 – 250 
Height (cm)     
   Mean ± STD 161 ± 8 166.3 ± 4.6 174.8 ± 2.0 182.9 ± 4.0 
   Median (IQR) 160 (156 – 166) 167.6 (165.1 – 169.9) 175.0 (173.0 – 176.8) 182.9 (180.1 – 185.4) 
   Range 121 – 186 132.1 – 171.5 172.0 – 177.8 178.1 – 200.7 
Weight (kg)*     
   Mean ± STD 71.9 ± 17.0 76.9 ± 14.3 85.8 ± 16.2 92.6 ± 17.9 
   Median (IQR) 69.0 (60 – 81.2) 75.1 (68.0 – 85.0) 83.9 (75.2 – 94.4) 90.7 (80.5 – 102.1) 
   Range 37.2 – 142.7 31.3 – 186.4 34.1 – 161.9 37.2 – 188.2 
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BMI     
   Mean ± STD 27.8 ± 6.5 27.8 ± 5.3 28.1 ± 5.2 27.7 ± 5.2 
   Median (IQR) 26.6 (23.4 – 31.3) 27.4 (24.4 – 30.6) 27.4 (24.7 – 30.7) 27.1 (24.1 – 30.5) 
   Range 14.2 – 64.3 11.8 – 70.6 11.4 – 51.2 11.5 – 56.3 
Lean Body Mass (kg)     
   Mean ± STD 45.2 ± 6.6 52.1 ± 5.1 57.9 ± 5.5 62.9 ± 6.4 
   Median (IQR) 44.8 (40.5 – 49.1) 51.8 (49.0 – 55.1) 57.3 (54.4 – 60.9) 62.1 (58.5 – 66.4) 
   Range 26.5 – 69.5 35.9 – 86.8 40.0 – 83.9 43.8 – 94.3 
Ischaemic 277 (34.9%) 580 (65.5%) 617 (66.0%) 522 (59.3%) 
Hypertension** 363 (45.9%) 392 (44.3%) 419 (45.1%) 399 (45.3%) 
NYHA     
   Class II 315 (39.7%) 442 (49.9%) 500 (53.5%) 468 (53.1%) 
   Class III 433 (54.5%) 409 (46.2%) 408 (43.6%) 393 (44.6%) 
   Class IV 46 (5.8%) 35 (4.0%) 27 (2.9%) 20 (2.3%) 
Baseline MLwHF     
   Mean ± STD 48.0 ± 24.0 40.3 ± 23.3 40.9 ± 23.5 41.6 ± 23.6 
   Median (IQR) 48 (28 – 67) 38.5 (21 – 57) 40 (21 – 59) 40 (22 – 59) 
   Range 0 – 105  0 - 105 0 - 101 0 – 100 
LBBB*** 704 (89.0%) 679 (77.0%) 686 (73.8%) 669 (76.4%) 
RBBB*** 29 (3.7%) 89 (10.1%) 103 (11.1%) 90 (10.3%) 
LVEF (%)     
   Mean ± STD 24.4 ± 6.2 24.1 ± 6.5 24.2 ± 6.1 23.9 ± 6.4 
   Median (IQR) 24.2 (20.0 – 28.3) 24.4 (20.0 – 28.0) 24.5 (20.0 – 28.0) 24.0 (19.8 – 28.0) 
   Range 8.0 – 53.4 7.0 – 51.6 8.9 – 48.3 6.0 – 46.8 
LVEDD****     
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   Mean ± STD 6.6 ± 0.9 6.9 ± 0.9 7.0 ± 0.9 7.1 ± 0.9 
   Median (IQR) 6.5 (6.0 – 7.2) 6.8 (6.2 – 7.4) 7.0 (6.4 – 7.5) 7.0 (6.5 – 7.7) 
   Range 4.1 – 9.6 4.9 – 9.9 4.8 – 12.0 3.9 – 10.5 
LVESV*****     
   Mean ± STD 198.3 ± 85.4 224.9 ± 90.3 237.5 ± 93.4 260.4 ± 107.0 
   Median (IQR) 180.8 (137.9 – 241.1) 207.7 (164.5 – 267.8) 220.9 (175.2 – 282.4) 237.8 (183.1 – 307.7) 
   Range 47.6 – 555.7 65.7 – 759.2 75.0 – 826.1 82.1 – 862.0 
Baseline Medications     
   Beta Blocker 617 (77.7%) 679 (76.6%) 740 (79.1%) 693 (78.7%) 
   ACE/ARB****** 755 (95.3%) 841 (95.0%) 887 (95.4%) 839 (95.2%) 
   Digoxin****** 372 (47.0%) 342 (38.6%) 396 (42.6%) 421 (47.8%) 
   Diuretics****** 713 (90.0%) 780 (88.1%) 815 (87.6%) 763 (86.6%) 
   Spironolactone******* 355 (47.0%) 356 (45.6%) 389 (44.6%) 354 (42.8%) 
*57 Subjects with missing data 
**11 Subjects with missing data 
***17 Subjects with missing data 
****1023 subjects with missing data 
*****1417 Subjects with missing data 
******8 Subjects with missing data 
*******223 Subjects with missing data 
ACE=angiotensin converting enzyme inhibitor, AII= angiotensin II receptor inhibitor, BMI= body mass index, IQR= 
interquartile range, LVEF= left ventricular ejection fraction, LBBB= left bundle branch block, LVEDD= left ventricular 
end-diastolic diameter, LVESV= left ventricular end-systolic volume, MLwHF= Minnesota Living with Heart Failure 
Questionnaire, NYHA New York Heart Association class, RBBB= right bundle branch block, STD= standard deviation
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Table 3. Estimated Event Rates by Sex, Aetiology, and Randomization Arm 
Sex Ischaemic CRT (N=1970) Control 
(N=1809) 
QRS Duration 
Median (25th – 
75th Percentile) 
Event Rates per 100 Pt 
Years 
Mortality Rate 
(Mortality/HFH Rate) 
Empirical 
Hazard Ratio: 
Mortality 
(Mortality/HFH) 
CRT Control 
Men Yes 1004 (65.1%) 885 (63.4%) 160 (140 – 172)  7.8 (14.4) 11.1 (21.3) 0.70 (0.68) 
 No 538 (34.9%) 511 (36.6%) 164 (150 – 180) 4.5 (10.1) 7.7 (16.1) 0.59 (0.62) 
Women Yes 155 (36.2%) 143 (34.6%) 160 (140 – 172) 8.0 (15.0) 11.8 (24.7) 0.67 (0.61) 
 No 273 (63.8%) 270 (65.4%) 160 (152 – 178)  3.3 (6.4) 7.2 (16.3) 0.47 (0.40) 
HFH= heart failure related hospitalization  
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Table4. Estimated Event Rates by Sex, Tercile of Height and Randomization Arm 
Gender Subgroup by Ht: Median (IQR) CRT Arm Control Arm QRS Duration 
Median (25th – 75th 
Percentile) 
Event Rates per 100 Pt Years 
Mortality Rate 
(Mortality/HFH Rate) 
Empirical 
Hazard Ratio: 
Mortality 
(Mortality/HFH) CRT Control 
Women Lower 50%: 156.0 (152.4 – 158.0 cm) 205 192 160 (150 – 171) 4.38 (9.34) 8.02 (20.86) 0.55 (0.48) 
Upper 50%: 166.1 (163.1 – 169.9 cm) 201 196 160 (150 – 178) 4.21 (8.66) 7.33 (15.13) 0.57 (0.57) 
Men T1: 167.6 (165.0 -169.9 cm) 460 428 160 (144 – 176) 5.59 (10.52) 10.12 (19.86) 0.55 (0.53) 
 T2: 175.0 (172.9 – 176.8cm) 475 460 160 (140 – 175) 5.18 (12.91) 7.64 (17.51) 0.68 (0.74) 
 T3: 182.9 (180.1 – 185.4cm) 493 389 160 (144 – 180) 5.41 (11.89) 6.86 (15.73) 0.79 (0.76) 
Ht= height, HFH= heart failure related hospitalization 
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Table 5. Main Modelling Results for Time to All-Cause Mortality/HF Hospitalisation 
Effect Mortality/HF Hospitalisation Mortality 
Effect (Hazard 
Ratio) 
P-value Effect (Hazard Ratio) P-value 
Main Effects      
   CRT Therapy 0.362 0.64 0.452 0.16 
   Age at Baseline 1.018 <0.0001 1.039 <0.0001 
   NYHA II 0.640 <0.0001 0.581 0.0001 
   NYHA IV 1.934 <0.0001 2.213 <0.0001 
   Ischaemic 1.444 <0.0001 1.667 <0.0001 
   QRS Duration 1.000 0.92 1.006 0.044 
   LVEF 0.973 <0.0001 0.960 <0.0001 
   Beta Blocker Usage at baseline 0.818 0.016 0.786 0.028 
   Supine Systolic BP at baseline 0.989 <0.0001 0.987 <0.0001 
   Height 0.992 0.096 0.999 0.92 
Interaction Effects of CRT with     
   QRS Duration (Linear) 0.989 0.0002 0.986 0.0011 
   QRS Duration (Non-linear) See Figure 0.0031 N/A N/A 
   Height (Linear) 1.019 0.013 1.018 0.083 
   Height (Non-linear) See Figure 0.66 N/A N/A 
Frailty (Study to Study 
Differences) 
 <0.0001  <0.0001 
Items in bold are statistically significant at p<0.05 
HF= heart failure, LVEF= left ventricular ejection fraction  
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Figure 2B 
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Figure 3A 
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Figure 3B 
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Figure 4A 
 
V2 EJHF 
34 
 
 
Figure 4B 
 
 
  
V2 EJHF 
35 
 
 
Supplementary Appendix 
Supplementary Table 1. Modelling Results for Time to All-Cause  
Mortality/HF Hospitalisation Among Subjects With LVEDD 
Effect Mortality/HF Hospitalisation 
Effect (Hazard 
Ratio) 
P-value 
Main Effects    
   CRT Therapy 0.362 0.50 
   Age at Baseline 1.014 0.0025 
   NYHA II 0.610 0.0003 
   NYHA IV 1.895 0.0001 
   Ischaemic 1.627 <0.0001 
   QRS Duration 0.997 0.30 
   LVEF 0.974 0.0011 
   Beta Blocker Usage at baseline 0.851 0.097 
   Supine Systolic BP at baseline 0.993 0.0068 
   Height 1.209 0.0045 
   LVEDD 0.983 0.0034 
Interaction Effects of CRT with   
   QRS Duration (Linear) 0.991 0.012 
   QRS Duration (Non-linear) Non-constant 0.0011 
   Height (Linear) 1.028 0.0029 
   LVEDD (Linear) 0.918 0.36 
Frailty (Study to Study Differences)  <0.0001 
Items in bold are statistically significant at p<0.05 
Only 2473 of the 3496 subjects with height available also had LVEDD and were included in this sub-analysis 
 
 
